Ding Ding Email & Phone Number

Ding Ding, Ph.D. is a partner of Mianus Capital, a venture capital fund focusing on investing in companies developing breakthrough therapeutics for ophthalmology, oncology, respiratory and neurological diseases globally. She is also the founder/chairwoman of Augere Group, which offers strategic-CFO-on-demand services to healthcare and climate tech companies globally. Dr. Ding serves on the board of China Institute, a renowned U.S. non-profit organisation of 97 year history dedicated to deepening the US/China relationship through business, art, culture, and education programs. Prior to her current endeavour, Dr. Ding spent 21 years in healthcare investment banking and equity research in New York and Asia with various leading global banks, and served as the CFO of Structure Therapeutics, a Nasdaq-listed US biotech company. For her banking career, Dr. Ding was most recently the head of Asia Healthcare Investment Banking (IBD) at Credit Suisse (CS), and the head of China healthcare IBD at Barclays and Nomura prior to CS. Dr. Ding and her team advised some of the most important landmark transactions with $70+ billion deal value over 10 years, including: 4 largest Asia life science IPOs ($903m for Beigene, $750m for Zai Lab, $453m for Junshi, $451m for Everest); Largest pre-IPO financing for a CART company ($186 m for Carsgen); Largest CRO IPO in Asia ($1.59bn for Tigermed); Largest cancer genomic IPO on Nasdaq ($256m for Genetron); 1st chapter 18A medtech IPO ($381m for Venus Medtech); 2 largest private financing for Asian Healthcare companies ($600m for Ruipeng, and $500m for WeDoctor); Two largest Asian healthcare follow-on ($2.1 bn for Beigene and $1.3 bn for AliHealth); Largest Asian healthcare SPAC/de SPAC (New Frontier’s $1.4 bn acquisition of Chindex); Largest Chinese outbound Healthcare acquisition (Luye’s A$938m acquisition of Healthe in Australia); 2nd largest US acquisition of Chinese medtech company (Stryker's $764m acquisition of Trauson). Prior to her banking career, Dr. Ding spent 9 years as an equity research analyst, covering US large cap pharma at Lehman Brothers in the #1 Institutional Investor ranked research team in New York, and as the head of China healthcare equity research at UBS in Hong Kong. Dr. Ding received her Ph.D. in pharmacology/neuroscience from State University of New York, Downstate Medical Center, her MBA in finance from the Wharton School, University of Pennsylvania, and BS in electrical engineering from Huazhong University of Science and Technology in China.